SXTP
NASDAQ · Pharmaceuticals
60 Degrees Pharma Inc
$1.12
-0.03 (-2.61%)
Financial Highlights (FY 2026)
Revenue
5.54M
Net Income
-28,971,783
Gross Margin
44.5%
Profit Margin
-522.7%
Rev Growth
+40.2%
D/E Ratio
0.04
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 44.5% | 44.5% | 46.3% | 46.3% |
| Operating Margin | -550.6% | -495.5% | 30.7% | 30.1% |
| Profit Margin | -522.7% | -496.6% | 23.1% | 21.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 5.54M | 3.95M | 862.6K | 990.0K |
| Gross Profit | 2.47M | 1.76M | 399.5K | 458.5K |
| Operating Income | -30,519,499 | -19,590,292 | 264.9K | 298.0K |
| Net Income | -28,971,783 | -18,596,822 | 198.9K | 215.4K |
| Gross Margin | 44.5% | 44.5% | 46.3% | 46.3% |
| Operating Margin | -550.6% | -495.5% | 30.7% | 30.1% |
| Profit Margin | -522.7% | -496.6% | 23.1% | 21.8% |
| Rev Growth | +40.2% | +40.2% | -6.7% | +4.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 64.6K | 64.6K | 1.77M | 1.68M |
| Total Equity | 1.46M | 1.46M | 3.39M | 2.90M |
| D/E Ratio | 0.04 | 0.04 | 0.52 | 0.58 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -30,349,019 | -20,563,132 | 334.7K | 417.4K |
| Free Cash Flow | — | — | 224.8K | 208.8K |